Skip to search formSkip to main contentSkip to account menu

Systemic Lupus Erythematosus Disease Activity Index

Known as: SLEDAI 
A clinical index for the measurement of disease activity in systemic lupus erythematosus. The index utilizes 24 weighted variables that measure… 
National Institutes of Health

Related topics

Related topics

1 relation
Research or Clinical Assessment Tool

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2008
Highly Cited
2008
CD4+CD25+ regulatory T cells (TREG) in systemic lupus erythematosus (SLE) patients: the possible influence of treatment with corticosteroids.
Highly Cited
2008
Highly Cited
2008
Elevated serum decoy receptor 3 with enhanced T cell activation in systemic lupus erythematosus
Decoy receptor 3 (DcR3/TR6) is a decoy receptor for the Fas ligand (FasL) and can inhibit FasL‐induced apoptosis. It has been… 
Highly Cited
2007
Highly Cited
2007
Role of pathogenic auto-antibody production by Toll-like receptor 9 of B cells in active systemic lupus erythematosus.
OBJECTIVES Toll-like receptor 9 (TLR9) is a pattern-associated receptor functioning in innate immunity that may be involved in… 
Highly Cited
2002
Highly Cited
2002
Urinary soluble VCAM-1 in systemic lupus erythematosus: a clinical marker for monitoring disease activity and damage.
OBJECTIVE To determine the urinary levels of soluble vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion… 
2001
2001
Serum and in vitro production of IL-1 receptor antagonist correlate with C-reactive protein levels in newly diagnosed, untreated lupus patients.
OBJECTIVE To examine the correlation between C-reactive protein (CRP) and CRP-inducing cytokines (IL-1 beta, IL-6, TNF-alpha) and… 
Highly Cited
2000
Highly Cited
2000
Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity.
OBJECTIVE To determine whether vaccination of patients with systemic lupus erythematosus (SLE) with influenza virus vaccine is… 
Highly Cited
1999
Highly Cited
1999
Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation.
OBJECTIVE Most information available about the disease course of patients with systemic lupus erythematosus (SLE) is restricted… 
Highly Cited
1998
Highly Cited
1998
Effect of 1 year cyclosporine a treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study
Our objective was to determine the effect of 1 year low-dose cyclosporine A (CSA) treatment on disease activity and renal… 
1998
1998
A study of the association of HLA DR, DQ, and complement C4 alleles with systemic lupus erythematosus in Iceland
OBJECTIVE To perform an exploratory analysis of the relative contribution of single MHC genes to the pathogenesis of systemic… 
Highly Cited
1995
Highly Cited
1995
The value of complement activation products in the assessment of systemic lupus erythematosus flares.
Complement activation products (CAP) have been reported as sensitive markers of disease activity in systemic lupus erythematosus… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)